Flow cytometry analysis of T-cell leukemia cell lines CEM and Jurkat, the erythroleukemic cell line K562, the lymphoblastic cell line Raji, and the mantle cell lymphoma MAVER-1. Target cells MAVER-1 and Raji were CD20+ cell line. The CD20+ residuals of MAVER-1 and Raji cell lines existed as a majority population of around 99%. K562 and Jurkat were CD20 negative control cell lines, while CEM was a CD20 negative control cell line that expresses CD7.
Supplementary Figure 2: Antibody-binding capacity of CD16-BB-ζ and CD64-BB-ζ receptors in 293T cells. (A) 293T
cells, CD16-BB-ζ 293T cells, and CD64-BB-ζ 293T cells (referred to as 293T hCD16 or 293T hCD64 ) were incubated with human anti-CD20 APC antibody for 30 minutes, non-transduced 293T cells set as control; the amount of antibody bound was visualized with a anti-human CD20 antibody conjugated to APC by flow cytometry assay. CD16 or CD64 expressed nearly 100% in 293T cells (Data not shown).
(B) Summary of the antibody-binding capacity assays was illustrated in A (***P < 0.001 by t test). Data presented are the mean ± SD of three separate experiments.
Supplementary Figure 3: Recognition specificity of NK-92MI
hCD16 and NK-92MI hCD64 cells toward target cells expressing CD20. MAVER-1 cells were pre-incubated with 0.1 μg/ml rituximab or an isotype-matched control antibody CD138 (clone ID: 587CT7.3.6.5) which were previously made in our laboratory for 30 min, and then incubated with CFSE for 30 min, followed by coculture with NK-92MI, NK-92MI hCD16 or NK-92MI hCD64 cells for 4h. Then, the cytotoxicity of NK-92MI, NK-92MI hCD16 or NK-92MI hCD64 cells toward these pretreated targets at an E:T ratio of 2:1 were determined by CFSE/7-AAD assay. Data are presented as the mean ± SD of three separate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the isotype antibody-pretreated group in NK-92MI hCD16 or NK-92M IhCD64 cells.
